Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial
Nov 12, 2021 By MarketDepth
Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) reported that the Phase 3 PRESECO clinical trial that evaluates oral antiviral Avigan/Reeqonus for treatment of mild to moderate COVID-19 did not achieve statistical significance on its primary endpoint of time sustained clinical recovery. Additional analyses of trial data are under way. The clinical trial reviewed 1,231 patients with mild to moderate COVID-19 from 38 study sites across the United States, Brazil and Mexico.
“While we are disappointed by the topline results of the PRESECO trial, we remain steadfast in our belief that safe and effective oral antivirals are urgently needed for patients who are still struggling to overcome COVID-19. We wish to thank all the patients who participated, and hope that information obtained from our trial can help guide research and development around more potential treatment options for COVID-19. Appili remains committed to addressing the challenges posed by infectious diseases and we will continue developing our pipeline to improve patient lives around the world.”
Dr. Armand Balboni, Chief Executive Officer, Appili Therapeutics
The Phase 3 PRESECO trial is a double blind study, placebo controlled, random, and global security trial investigating the safety and efficiency of oral Avigan/Reeqonus in the early treatment for adults infected with COVID-19 that show mild to moderate symptoms.
